Spots Global Cancer Trial Database for fludarabine phosphate

Every month we try and update this database with for fludarabine phosphate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies	NCT01175785	Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo...	umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom...	6 Months - 45 Years	Nohla Therapeutics, Inc.
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer	NCT00004135	Kidney Cancer Melanoma (Skin)	filgrastim therapeutic all... cyclophosphamid... fludarabine pho... peripheral bloo...	18 Years - 65 Years	University of Chicago
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma	NCT00091143	Melanoma (Skin)	gp100 antigen incomplete Freu... keyhole limpet ... fludarabine pho... peripheral bloo...	18 Years -	National Cancer Institute (NCI)
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia	NCT00453388	Acute Myeloid L... de Novo Myelody... Fanconi Anemia Previously Trea...	Allogeneic Bone... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Total-Body Irra...	-	Fred Hutchinson Cancer Center
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma	NCT00907036	Lymphoma	alemtuzumab donor lymphocyt... cyclosporine fludarabine pho... melphalan allogeneic hema...	16 Years - 65 Years	National Cancer Institute (NCI)
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma	NCT02280525	Leukemia	Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine	18 Years - 80 Years	M.D. Anderson Cancer Center
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	NCT01823198	Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related...	Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological...	7 Years - 65 Years	M.D. Anderson Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Natural Killer Cell (CYNK-001) Infusions in Adults With AML	NCT04310592	Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML	CYNK-001	18 Years - 80 Years	Celularity Incorporated
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer	NCT00020176	Breast Cancer	filgrastim therapeutic all... cyclophosphamid... cyclosporine fludarabine pho... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	NCT01640301	Recurrent Adult... Recurrent Child... Secondary Acute... Therapy-Related... Donor Hematopoietic C... HLA-A*0201 Posi... Recurrent Acute...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... WT1-Sensitized ...	-	Fred Hutchinson Cancer Center
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	NCT05418088	Recurrent Acute... Recurrent B Acu... Recurrent B-Cel... Recurrent Chron... Recurrent High ... Recurrent Indol... Recurrent Non-H... Recurrent Trans... Refractory Acut... Refractory B Ac... Refractory B-Ce... Refractory Chro... Refractory High... Refractory Indo... Refractory Non-... Refractory Tran...	Anti-CD19/CD20/... Cyclophosphamid... Fludarabine Pho...	18 Years -	Ohio State University Comprehensive Cancer Center
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma	NCT00006184	Multiple Myelom...	Myeloma Immunog... Bortezomib Cyclophosphamid... Cyclosporine Doxorubicin hyd... Etoposide Fludarabine pho... Prednisone Vincristine Sul... Methotrexate GMCSF (granuloc... GCSF (granulocy...	18 Years - 75 Years	National Institutes of Health Clinical Center (CC)
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00119392	B-cell Chronic ... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac...	rituximab cyclosporine fludarabine pho... mycophenolate m... yttrium Y 90 ib... peripheral bloo... allogeneic hema... total-body irra...	18 Years -	Fred Hutchinson Cancer Center
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia	NCT00003145	Accelerated Pha... Childhood Chron... Chronic Myeloge... Chronic Phase o... Recurrent Disea...	Fludarabine Pho... Total-Body Irra... Nonmyeloablativ... Peripheral Bloo... Cyclosporine Mycophenolate M... Therapeutic All... Laboratory Biom...	- 74 Years	Fred Hutchinson Cancer Center
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission	NCT00070135	Adult Acute Mye... Acute Myeloid L...	filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema...	60 Years - 74 Years	Alliance for Clinical Trials in Oncology
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor	NCT01598025	Acute Leukemia Chronic Leukemi... Myelodysplastic... Non-Hodgkins Ly...	total-body irra... thiotepa fludarabine pho... melphalan anti-thymocyte ... allogeneic hema... peripheral bloo... laboratory biom...	- 19 Years	Memorial Sloan Kettering Cancer Center
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	NCT00004862	Leukemia	filgrastim oblimersen sodi... cytarabine fludarabine pho...	16 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia	NCT00003619	Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni...	filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo...	19 Years - 90 Years	National Cancer Institute (NCI)
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies	NCT02529813	Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni...	Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce...	1 Year - 80 Years	M.D. Anderson Cancer Center
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	NCT00357565	Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo...	filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ...	- 3 Years	Masonic Cancer Center, University of Minnesota
Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma	NCT00045513	Leukemia Lymphoma	7-hydroxystauro... fludarabine pho...	18 Years -	University Health Network, Toronto
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas	NCT00043979	Sarcoma	F-18 Fluorodeox... therapeutic all... cyclophosphamid... cyclosporine doxorubicin hyd... etoposide fludarabine pho... melphalan prednisone sirolimus tacrolimus vincristine sul... peripheral bloo... Filgrastim Peripheral Bloo...	5 Years - 35 Years	National Institutes of Health Clinical Center (CC)
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	NCT05400122	Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye...	Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ...	18 Years -	Case Comprehensive Cancer Center
Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia	NCT00276809	Chronic Lymphoc...	alemtuzumab filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years - 60 Years	German CLL Study Group
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis	NCT02528877	Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo...	Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus	18 Years - 75 Years	City of Hope Medical Center
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma	NCT05470283	Tumor Metastatic Mela... Melanoma	OBX-115 Acetazolamide Cyclophosphamid... Furosemide Mesna Fludarabine Pho...	18 Years -	M.D. Anderson Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	NCT01471444	Disorder Relate... Leukemia Transplantation...	Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate	3 Years - 70 Years	M.D. Anderson Cancer Center
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies	NCT06383572	Lymphodepleting... Myeloid Maligna...	Cyclophosphamid... Fludarabine pho... Decitabine	18 Years - 75 Years	M.D. Anderson Cancer Center
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma	NCT00397800	Lymphoma	rituximab cyclophosphamid... fludarabine pho... yttrium Y 90 ib...	50 Years - 75 Years	Technical University of Munich
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma	NCT00062036	Melanoma (Skin)	aldesleukin filgrastim incomplete Freu... interleukin-2 g... therapeutic tum... cyclophosphamid... fludarabine pho...	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
Cellular Therapy With Cord Blood Cells	NCT00427557	Multiple Myelom... Leukemia Lymphoma	Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo...	- 80 Years	M.D. Anderson Cancer Center
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02057770	Leukemia, Myelo...	busulfan fludarabine pho... total-body irra... Stem cell trans... cyclophosphamid... tocilizumab	18 Years -	Washington University School of Medicine
Randomized Double Cord Blood Transplant Study	NCT00067002	Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H...	Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra...	1 Month - 80 Years	M.D. Anderson Cancer Center
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	NCT00024440	Leukemia	filgrastim oblimersen sodi... cyclophosphamid... fludarabine pho...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	NCT00278213	Prolymphocytic ...	alemtuzumab cyclophosphamid... fludarabine pho... mitoxantrone hy...	18 Years - 70 Years	German CLL Study Group
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)	NCT00941928	Leukemia Pediatric Cance...	Epratuzumab Fludarabine Cyclophosphamid... Mesna Infusion of NK ... Interleukin-2	-	M.D. Anderson Cancer Center
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	NCT03602898	Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related...	Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra...	- 65 Years	Fred Hutchinson Cancer Center
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases	NCT06013423	Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid...	Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ...	6 Months - 65 Years	Fred Hutchinson Cancer Center
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia	NCT01824693	Juvenile Myelom...	Allogeneic Hema... Busulfan Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Pharmacological... Tacrolimus	3 Months - 18 Years	Children's Oncology Group
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma	NCT00324623	Melanoma (Skin)	Melan-A VLP vac... adoptive immuno... therapeutic aut... cyclophosphamid... fludarabine pho...	18 Years - 75 Years	Centre Hospitalier Universitaire Vaudois
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT01503242	Plasma Cell Mye... Refractory Plas...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Total-Body Irra... Yttrium Y 90 An...	18 Years - 65 Years	Fred Hutchinson Cancer Center
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies	NCT06383572	Lymphodepleting... Myeloid Maligna...	Cyclophosphamid... Fludarabine pho... Decitabine	18 Years - 75 Years	M.D. Anderson Cancer Center
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission	NCT00101140	Adult Acute Ery... Adult Acute Mon... Adult Acute Mye...	anti-thymocyte ... fludarabine pho... thiotepa biological ther... bone marrow abl... chemotherapy non-specific im... peripheral bloo... radiation thera...	18 Years - 59 Years	Eastern Cooperative Oncology Group
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)	NCT02441803	Leukemia	Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin	18 Years - 60 Years	M.D. Anderson Cancer Center
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT02048813	Anemia Chronic Lymphoc... Small Lymphocyt...	Cyclophosphamid... Fludarabine Pho... Ibrutinib Laboratory Biom... Pharmacogenomic... Quality-of-Life... Rituximab	18 Years - 70 Years	National Cancer Institute (NCI)
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT01256398	Acute Lymphobla... Adult B Acute L...	Alemtuzumab Allogeneic Hema... Autologous Hema... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Etoposide Phosp... Filgrastim Fludarabine Pho... In Vitro-Treate... Laboratory Biom... Leucovorin Calc... Melphalan Mercaptopurine Methotrexate Pegfilgrastim Pharmacological... Tacrolimus Vincristine Sul...	18 Years -	National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	NCT03241940	B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A...	1 Year - 30 Years	Stanford University
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia	NCT00002838	Leukemia	Filgrastim (G-C... Cyclophosphamid... Fludarabine Pho... Peripheral Bloo...	- 65 Years	M.D. Anderson Cancer Center
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors	NCT05672459	Solid Tumor	Single Injectio... Fludarabine pho... Cyclophosphamid... leukapheresis	18 Years -	M.D. Anderson Cancer Center
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention	NCT02423915	Leukemia Lymphoma	Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated...	18 Years - 80 Years	M.D. Anderson Cancer Center
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia	NCT05761171	Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe...	Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul...	1 Month - 6 Years	Children's Oncology Group
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia	NCT00612612	B-cell Chronic ... Leukemia Prolymphocytic ... Refractory Chro... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni...	obatoclax mesyl... fludarabine pho... rituximab laboratory biom...	18 Years -	National Cancer Institute (NCI)
Safety and Efficacy of Campath in Nonmyeloablative Transplantation	NCT00038844	Lymphoma Leukemia	Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab	- 70 Years	M.D. Anderson Cancer Center
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	NCT00027820	Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child...	Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M...	-	Fred Hutchinson Cancer Center
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma	NCT04579523	Plasma Cell Mye... Recurrent Plasm... Refractory Plas...	Allogeneic Hema... Astatine At 211... Cyclophosphamid... Fludarabine Pho... Total-Body Irra...	18 Years - 70 Years	Fred Hutchinson Cancer Center
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	NCT01471444	Disorder Relate... Leukemia Transplantation...	Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate	3 Years - 70 Years	M.D. Anderson Cancer Center
Cellular Therapy With Cord Blood Cells	NCT00427557	Multiple Myelom... Leukemia Lymphoma	Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo...	- 80 Years	M.D. Anderson Cancer Center
Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma	NCT00006233	Melanoma (Skin)	therapeutic all... cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera...	18 Years - 64 Years	Fred Hutchinson Cancer Center
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support	NCT00506857	Hematologic Mal...	Busulfan Fludarabine	- 75 Years	M.D. Anderson Cancer Center
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia	NCT00513747	Leukemia	rituximab fludarabine pho...	18 Years -	Alliance for Clinical Trials in Oncology
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission	NCT00305708	Congenital Ameg... Diamond-blackfa... Fanconi Anemia Leukemia Severe Congenit... Thrombocytopeni...	anti-thymocyte ... busulfan fludarabine pho... allogeneic bone... peripheral bloo... umbilical cord ... radiation thera...	- 17 Years	University of California, San Francisco
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT01251575	Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01707004	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute...	decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom...	18 Years - 75 Years	University of Wisconsin, Madison
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML	NCT00871689	Leukemia	aldesleukin cyclophosphamid... fludarabine pho... umbilical cord ... total-body irra...	- 45 Years	Masonic Cancer Center, University of Minnesota
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide	NCT00800839	Hematologic Dis... Leukemia Lymphoma Myeloma	Busulfan Fludarabine Cyclophosphamid...	6 Months - 75 Years	M.D. Anderson Cancer Center
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT03813147	Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel...	Azacitidine Cytarabine Fludarabine Pho... Methotrexate Pevonedistat Therapeutic Hyd...	1 Month - 21 Years	National Cancer Institute (NCI)
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma	NCT00608374	Lymphoma	chlorambucil fludarabine pho... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia	NCT00003729	Leukemia	cytarabine fludarabine pho... idarubicin	- 17 Years	European Organisation for Research and Treatment of Cancer - EORTC
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma	NCT02652468	Lymphoma	Fludarabine Pho... Mesna Cyclophosphamid... Total nodal irr... T Cell-Depleted... Allogeneic Hema... Peripheral Bloo... Mycophenolate M... Tacrolimus Rituximab	18 Years - 75 Years	University of Wisconsin, Madison
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)	NCT01019317	Leukemia AML MDS CML	Cytarabine Fludarabine	12 Years -	M.D. Anderson Cancer Center
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer	NCT00006261	Breast Cancer	therapeutic all... cyclophosphamid... docetaxel doxorubicin hyd... fludarabine pho... peripheral bloo...	18 Years - 60 Years	Case Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: